Incyte Zynyz Gains First-Line Approval in Japan for Anal Cancer

Event summary

  • Incyte Japan received approval from the Japan Ministry of Health, Labour and Welfare (MHLW) for Zynyz (retifanlimab) in combination with carboplatin and paclitaxel for first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC).
  • The approval is based on Phase 3 POD1UM-303/InterAACT2 trial data showing a 37% reduction in the risk of progression or death (p=0.0006) compared to placebo.
  • Zynyz’s approval marks the first and only first-line treatment option for SCAC in Japan.
  • This is the second regulatory approval for Zynyz in advanced SCAC, following FDA approval in the U.S. in May 2025.

The big picture

The approval of Zynyz in Japan underscores the growing importance of immunotherapy in treating rare cancers like SCAC. While SCAC represents a small patient population (approximately 0.26-0.41 per 100,000 persons in Japan), the lack of effective first-line treatments created a significant unmet need. Incyte's success in securing this approval, following the FDA, positions them as a leader in this niche oncology space, but also highlights the challenges of commercializing therapies for rare diseases.

What we're watching

Commercialization
The speed of Zynyz adoption in Japan will depend on pricing, reimbursement, and physician familiarity with the combination therapy, given the rarity of SCAC.
Regulatory Risk
The EMA’s decision on the Type II variation Marketing Authorization Application will be a key indicator of retifanlimab’s broader regulatory trajectory in Europe.
Competitive Landscape
While currently the only first-line option, the SCAC treatment landscape is likely to evolve, and Incyte must anticipate and address potential competition from other immunotherapy or targeted therapies.

Related topics

Regulatory Approval